USPTO serial 79433020
BESPARK
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Aug 25, 2026
- Examiner
- MALYSZEK, KIMBERLY RAY
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with BESPARK?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Viral vaccines; vaccines for human use; cells for medical use; antibodies for medical purposes; pharmaceutical preparations for use in oncology or the treatment of solid tumor oncological diseases; pharmaceutical preparations and substances for use in oncology for the treatment of solid tumor oncological diseases; biological preparations for medical purposes for the treatment of solid tumor oncological diseases; chemical preparations for medical purposes, namely, for the treatment of solid tumor oncological diseases; all the foregoing excluding preparations for the diagnosis or treatment of retinal degenerative disorders, hematologic disorders, and hematologic diseases | ACTIVE | — |
| 042 | Scientific laboratory services; scientific analytical laboratory services; technology consultation in the field of artificial intelligence; research in the field of artificial intelligence technology; computer system analysis; design of computer-simulated models; computer software design for others; biochemistry services, namely, biochemical analysis services; medical research laboratories; chemistry services, namely, research and development services in the field of chemistry; chemical laboratories; chemical analysis; conducting technical project studies, namely, conducting feasibility studies in the field of new technologies; electronic data storage; provision of research services, namely, medical research services; biomedical research services; research relating to biotechnology, namely, biotechnology research; pharmaceutical research services; bacteriological research; chemical research; medical and pharmacological research services; research and development of new products for others; scientific research and development services; pharmaceutical research and development; medical and scientific research, namely, conducting clinical trials for others; technology advisory services relating to gene therapy research; scientific research in the field of gene therapy; culturing of cells for others for scientific research purposes; research and development services relating to vaccines; research and development of vaccines and medicines; medical research; scientific research for medical purposes in the area of cancerous diseases; medical research in the field of oncology; platform as a service (PAAS) featuring computer software platforms for use in bioprocess data modeling, simulation of biopharmaceutical manufacturing processes, digital-twin modeling of cell-culture and biologics production processes, and analysis of bioprocess development data; software engineering services for data processing programs; technological consultancy services for digital transformation; technological consultancy, namely, computer technology consultancy; technological research relating to bioprocessing, biotechnology, cell-line development, process development, analytical development, product validation, biologics, biosimilars, viral vectors, vaccines, ATMPs, and bionanoparticles; chemical technological research, namely, technological research in the field of chemistry; consultancy services relating to technological research, namely, technology consultation and research in the field of biotechnology, bioprocessing, cell-line development, process development, analytical development, and biopharmaceutical product validation; technical writing; scientific research; scientific and technological services, namely, computer aided scientific research services in the field of biotechnology, bioprocessing, cell-line development, process development, analytical development, and biopharmaceutical product validation; scientific research and development; Scientific and technological services, namely, scientific research and analysis in the field of biotechnology, bioprocessing, cell-line development, process development, analytical development, and biopharmaceutical product validation; scientific research in the field of genetics and genetic engineering; scientific research in the field of genetics; biological analysis; biochemical analysis services; scientific and technological services, namely, scientific analysis in the field of biotechnology, bioprocessing, cell-line development, process development, analytical development, and biopharmaceutical product validation; consultancy in the field of scientific research, namely, scientific research consultancy; scientific and technological services, namely, scientific research, scientific analysis, scientific testing, and product validation for quality evaluation purposes in the field of biotechnology, bioprocessing, cell-line development, process development, analytical development, and biopharmaceutical product validation; testing of materials, authentication in the field of biopharmaceutical raw materials, biologics, biosimilars, viral vectors, vaccines, ATMPs, and bionanoparticles and quality control for others; research laboratory analysis services in the field of bacteriology; technical consultancy in the field of industrial research; computer programming services for the analysis of data; computer design and programming services, namely, computer programming and software design; analysis of product development, namely, product research and development; quality assurance consultancy, namely, consultancy related to quality assurance services in the field of biopharmaceutical manufacturing, bioprocessing, cell-culture processes, and biologics development; consultancy services relating to quality control, namely, Consultancy relating to inspection of food processing facilities for quality control purposes; computer aided scientific testing, namely, computer aided genetic testing for scientific research purposes; computer aided testing services, namely computer aided product safety testing; engineering testing, namely, testing of biopharmaceutical manufacturing equipment, bioreactor systems, cell-culture systems, and bioprocessing systems for scientific research and product-development purposes; conducting of quality control tests, namely, quality control testing for others; technical measuring, namely, technical measuring and testing of biopharmaceutical process parameters, namely, cell-culture performance, bioreactor process performance, product quality attributes, and analytical assay performance, all for quality assurance purposes; scientific testing services, namely, scientific testing of biopharmaceutical products, biologics, biosimilars, viral vectors, vaccines, ATMPs, bionanoparticles, cell cultures, and bioprocess materials; development and test of chemical production methods; development of measuring and testing methods, namely, development and establishment of testing specifications and procedures in the field of biopharmaceutical manufacturing, bioprocessing, cell-line development, process development, analytical development, and product validation for quality evaluation purposes; development of testing methods, namely, development and establishment of testing specifications and procedures in the field of biopharmaceutical manufacturing, bioprocessing, cell-line development, process development, analytical development, and product validation for quality evaluation purposes; design and testing for new product development; analysis and evaluation of product development, namely, product research and development evaluation for biopharmaceutical products, biologics, biosimilars, viral vectors, vaccines, ATMPs, and bionanoparticles for quality evaluation purposes; biological research laboratory services; product quality control testing, namely, quality control testing of products; product testing; product quality testing; process monitoring for quality assurance, namely, monitoring of biopharmaceutical manufacturing and bioprocessing processes for quality assurance purposes; quality assessment, namely, quality assessment services for biopharmaceutical products, biologics, biosimilars, viral vectors, vaccines, ATMPs, bionanoparticles, cell cultures, and bioprocess materials for quality evaluation purposes; quality control for others; inspection of pharmaceuticals; scientific risk assessment, namely, scientific risk assessment services for biopharmaceutical process development, analytical development, product validation, and bioprocess scale-up; scientific laboratory services relating to the production of monoclonal antibodies; research and development services in the field of antibodies; scientific research and development services in the field of antibody technology; cell culture services for scientific and research purposes, for others | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 25, 2026 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Aug 25, 2026 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jul 7, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jul 7, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jul 2, 2026 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Jul 1, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jun 17, 2026 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jun 17, 2026 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Jun 5, 2026 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jun 5, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jun 5, 2026 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jun 5, 2026 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jun 5, 2026 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jun 3, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 3, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 3, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 4, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 12, 2026 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jan 23, 2026 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jan 23, 2026 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Dec 20, 2025 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Dec 19, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 18, 2025 | RFWR | NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW | — |
| Nov 12, 2025 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Nov 11, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 23, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 22, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Sep 22, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Sep 18, 2025 | SDRC | SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB | — |